Clinical trial
LT F-up Study 16-20 Yrs After Vaccine Dose of Hepatitis B With/Without HBIg in…
NCT00240526 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00240526 |
|---|---|
| Title | LT F-up Study 16-20 Yrs After Vaccine Dose of Hepatitis B With/Without HBIg in Newborns to HBeAg+ Mothers |
| Official title | Comparative Study of the Immunogenicity and Protective Efficacy of GlaxoSmithKline Biologicals' Rec-DNA Hepatitis B Vaccine With or Without Hepatitis B Immunoglobulins (HBIg) in Newborns of HBeAg+ Mothers. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hepatitis B |
| Intervention type | Biological |
| Interventions | Engerix™ -B, Hepatitis B immunoglobulin (HBIg) |
| Enrollment | 79 |
| Start date | Oct 1, 2003 |
| Primary completion | Mar 1, 2010 |
| Completion | Mar 1, 2010 |
| First posted | Oct 18, 2005 |
| Last update posted | Dec 7, 2016 |
| Countries | Thailand |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: